BR9506667A - Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol - Google Patents

Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol

Info

Publication number
BR9506667A
BR9506667A BR9506667A BR9506667A BR9506667A BR 9506667 A BR9506667 A BR 9506667A BR 9506667 A BR9506667 A BR 9506667A BR 9506667 A BR9506667 A BR 9506667A BR 9506667 A BR9506667 A BR 9506667A
Authority
BR
Brazil
Prior art keywords
preparation
pyrimidine
diamino
cyclo
amino
Prior art date
Application number
BR9506667A
Other languages
English (en)
Inventor
Susan Mary Daluge
Martin Michael Tolar
Michelle Joanne Ferry Fugett
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9506667(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of BR9506667A publication Critical patent/BR9506667A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9506667A 1994-02-04 1995-02-03 Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol BR9506667A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402161A GB9402161D0 (en) 1994-02-04 1994-02-04 Chloropyrimidine intermediates
PCT/GB1995/000225 WO1995021161A1 (en) 1994-02-04 1995-02-03 Chloropyrimide intermediates

Publications (1)

Publication Number Publication Date
BR9506667A true BR9506667A (pt) 1997-09-16

Family

ID=10749873

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506667A BR9506667A (pt) 1994-02-04 1995-02-03 Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol

Country Status (28)

Country Link
US (8) US6448403B1 (pt)
EP (1) EP0741710B1 (pt)
JP (1) JP3670012B2 (pt)
KR (1) KR100355983B1 (pt)
CN (2) CN1161343C (pt)
AT (1) ATE192742T1 (pt)
AU (1) AU690203B2 (pt)
BR (1) BR9506667A (pt)
DE (1) DE69516847T2 (pt)
DK (1) DK0741710T3 (pt)
ES (1) ES2148486T3 (pt)
FI (1) FI112477B (pt)
GB (1) GB9402161D0 (pt)
GR (1) GR3033850T3 (pt)
HK (1) HK1004087A1 (pt)
HU (1) HU223096B1 (pt)
IL (1) IL112539A (pt)
MX (1) MX9603091A (pt)
MY (1) MY113775A (pt)
NO (1) NO310819B1 (pt)
NZ (1) NZ278948A (pt)
PL (1) PL183885B1 (pt)
PT (1) PT741710E (pt)
RU (1) RU2140913C1 (pt)
SG (1) SG47918A1 (pt)
TW (1) TW390877B (pt)
WO (1) WO1995021161A1 (pt)
ZA (1) ZA95884B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
SK284810B6 (sk) 1997-05-13 2005-12-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purín-9-yl)-2-cyklopentén-1-metanolu
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
JP2001522850A (ja) * 1997-11-12 2001-11-20 グラクソ グループ リミテッド キラルヌクレオシド類似体の製造法
CZ298144B6 (cs) * 1997-11-27 2007-07-04 Lonza Ag Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu
EP1188750B1 (de) * 1998-12-21 2003-10-15 Lonza AG Verfahren zur Herstellung von 2,5-Diamino-4,6-dihalogenpyrimidinen
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
EP2336133A1 (en) * 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR100573859B1 (ko) * 2002-07-15 2006-04-25 경동제약 주식회사 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
US20040266795A1 (en) * 2003-04-30 2004-12-30 Genny Shamai Process for the preparation of famciclovir
JPWO2004103979A1 (ja) * 2003-05-26 2006-07-20 住友化学株式会社 N−(2−アミノ−4,6−ジクロロピリミジン−5−イル)ホルムアミドの製造方法
KR100573860B1 (ko) * 2003-06-13 2006-04-25 경동제약 주식회사 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
US20050143400A1 (en) * 2003-09-04 2005-06-30 Genny Shamai Process for preparing famciclovir
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
BRPI0414533A (pt) * 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
DE102004002055A1 (de) * 2004-01-15 2005-08-11 Degussa Ag Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin
JP4468989B2 (ja) * 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Rtp801阻害剤の治療への使用
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
WO2008072074A1 (en) * 2006-12-11 2008-06-19 Aurobindo Pharma Limited An improved process for the preparation of purine derivative
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP2170840A1 (en) * 2007-06-21 2010-04-07 Aurobindo Pharma Ltd An improved process for preparing purine derivative
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer
CN104672239A (zh) * 2013-11-26 2015-06-03 上海迪赛诺化学制药有限公司 一种采用一锅法制备阿巴卡韦式v中间体的工艺
CN109456329B (zh) * 2018-11-19 2021-03-09 迪嘉药业集团有限公司 一种泛昔洛韦的制备方法
CN113292507B (zh) * 2021-06-25 2022-07-19 潍坊奥通药业有限公司 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
US4965270A (en) 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
GB8724765D0 (en) 1987-10-22 1987-11-25 Beecham Group Plc Process
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4916224A (en) 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB8916698D0 (en) 1989-07-21 1989-09-06 Beecham Group Plc Novel process
GB8918827D0 (en) 1989-08-17 1989-09-27 Beecham Group Plc Novel compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
SK279618B6 (sk) * 1992-01-22 1999-01-11 Lonza A.G. (Dir.:Basel) N-5-chránené 2,5-diamino-4,6-dichlórpyrimidíny a s
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation

Also Published As

Publication number Publication date
GR3033850T3 (en) 2000-10-31
US6087501A (en) 2000-07-11
US20030187263A1 (en) 2003-10-02
HK1004087A1 (en) 1998-11-13
SG47918A1 (en) 1998-04-17
IL112539A (en) 2000-08-31
US6555687B1 (en) 2003-04-29
CN1139924A (zh) 1997-01-08
ES2148486T3 (es) 2000-10-16
RU2140913C1 (ru) 1999-11-10
DK0741710T3 (da) 2000-08-14
US6448403B1 (en) 2002-09-10
US5917042A (en) 1999-06-29
TW390877B (en) 2000-05-21
IL112539A0 (en) 1995-05-26
FI963070A (fi) 1996-08-02
EP0741710A1 (en) 1996-11-13
PT741710E (pt) 2000-09-29
MY113775A (en) 2002-05-31
DE69516847T2 (de) 2000-10-26
US6870053B2 (en) 2005-03-22
CN1161343C (zh) 2004-08-11
KR100355983B1 (ko) 2002-12-28
NO310819B1 (no) 2001-09-03
JP3670012B2 (ja) 2005-07-13
HUT75300A (en) 1997-05-28
AU690203B2 (en) 1998-04-23
CN1388123A (zh) 2003-01-01
GB9402161D0 (en) 1994-03-30
US6552193B1 (en) 2003-04-22
ATE192742T1 (de) 2000-05-15
DE69516847D1 (de) 2000-06-15
US20020173649A1 (en) 2002-11-21
HU9602114D0 (en) 1996-09-30
FI963070A0 (fi) 1996-08-02
CN1105109C (zh) 2003-04-09
PL183885B1 (pl) 2002-07-31
ZA95884B (en) 1996-08-05
NO963239L (no) 1996-10-02
MX9603091A (es) 1998-01-31
FI112477B (fi) 2003-12-15
US5917041A (en) 1999-06-29
NZ278948A (en) 1998-01-26
HU223096B1 (hu) 2004-03-29
WO1995021161A1 (en) 1995-08-10
JPH09508412A (ja) 1997-08-26
EP0741710B1 (en) 2000-05-10
AU1543895A (en) 1995-08-21
PL315713A1 (en) 1996-11-25
NO963239D0 (no) 1996-08-02

Similar Documents

Publication Publication Date Title
BR9506667A (pt) Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol
ATE245646T1 (de) Therapeutische nukleoside
ES2149157T3 (es) Nuevo procedimiento para la preparacion de nucleotidos.
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
BR9808923A (pt) Composto, e, processo para fazer o mesmo
BR9811855A (pt) Processo para preparação de ácido l-ascórbico
BR0011996A (pt) Preparação de piperidin-4-onas substituìdas
CA2227762A1 (en) Substituted aminouracils
IT1293777B1 (it) Processo per la preparazione di tetraazamacrocicli
ES2169053T3 (es) Compuestos intermedios en la sintesis de cefalosporinas.
BR9807785A (pt) Processo para a preparação do composto, e, composto
BR9607850A (pt) Processo para a preparação de um composto e composto
DE69418050D1 (de) Antivirale analoge von difluorostaton
ES2152982T3 (es) Analogos de la difluoroestatona.
BR9906931A (pt) Triazepinonas, processo para sua preparação e sua aplicação terapêutica

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 03/02/2015